BTX - BTX STOCK NEWS

Brooklyn ImmunoTherapeutics (BTX) announced the issuance of 18 new patents and filing of 17 new patent applications in 2021, all exclusively licensed from Factor Bioscience. These patents cover advances in mRNA-based cellular reprogramming, gene editing, and nucleic acid delivery via ToRNAdo™ lipid nanoparticle technology. With over 70 issued patents and 60 pending applications, Brooklyn is positioned to enhance its therapeutic capabilities in cancer and genetic diseases.

The company’s lead program, IRX-2, shows promise in treating head and neck cancer.

Brooklyn ImmunoTherapeutics (Nasdaq: BTX) has been included in the ICE Biotechnology Index as of December 20, 2021. This inclusion reflects the company's recognition in the biotech sector, according to CEO Howard Federoff. The ICE Biotechnology Index tracks U.S.-listed biotechnology firms engaged in therapeutic research and development. Brooklyn is focused on innovative treatments for cancer, blood disorders, and monogenic diseases, with its lead program, IRX-2, currently in a Phase 2B clinical trial for head and neck cancer, showing promising survival benefits in earlier phases.

Brooklyn ImmunoTherapeutics, Inc. (Nasdaq: BTX) has been named to the Nasdaq Biotechnology Index, effective December 20, 2021. This inclusion signifies recognition of Brooklyn's potential in the biotech sector, as noted by CEO Howard Federoff. The Nasdaq Biotechnology Index tracks the performance of biotechnology and pharmaceutical securities. Brooklyn's advanced program, IRX-2, a human cell-derived cytokine therapy, is in Phase 2B trials for head and neck cancer, building on promising Phase 2A results demonstrating overall survival benefits.

BROOKLYN, Dec. 02, 2021 – Brooklyn ImmunoTherapeutics (Nasdaq: BTX) announced that President and CEO Howard Federoff, M.D., Ph.D. will present at two upcoming virtual conferences. He will speak at the Benzinga Global Small Cap Conference on December 8 at 4:40 PM EST, and at the MedInvest Oncology Investor Conference on December 9 at 11:20 AM EST. Both conferences will offer one-on-one meetings with management. Brooklyn is advancing treatments for cancer and blood disorders, including its human cell-derived therapy IRX-2, currently in Phase 2B trials for head and neck cancer.

Brooklyn ImmunoTherapeutics (Nasdaq: BTX) announces the appointment of Susan McClatchey as Vice President, Head of Quality, enhancing its gene editing and cell therapy drug development platform. McClatchey brings nearly 30 years of experience in the industry, previously working at IQVIA and other notable firms. Her expertise is expected to support a significant ramp-up in drug development activities. The company is currently advancing its IRX-2 therapy for head and neck cancer, having shown survival benefits in prior trials. Brooklyn also issued a stock option grant to McClatchey for 70,000 shares.

Brooklyn ImmunoTherapeutics, Inc. (Nasdaq: BTX) announced on November 19, 2021, that it filed a registration statement with the SEC for a proposed public offering of 6,281,454 shares of its common stock, to be sold by certain stockholders. The shares were received in connection with the acquisition of Novellus, Inc. in July 2021. Importantly, Brooklyn will not receive any proceeds from this sale. The registration has not yet become effective, and the offering will only occur post-registration.

Brooklyn ImmunoTherapeutics (Nasdaq:BTX) reported financial results for Q3 2021, highlighting a significant transition to the Nasdaq Global Market and the acquisition of Novellus Therapeutics. The company’s Q3 operating expenses surged to $86.3 million, largely due to $80.5 million in research and development costs from the Novellus acquisition. The net loss for the quarter was $86.1 million, compared to $2.0 million the previous year. Brooklyn has approximately $24.4 million in cash, expected to fund operations into 2023.

Brooklyn ImmunoTherapeutics (ticker: BTX) announced its transfer from NYSE American to Nasdaq, effective October 22, 2021. The common stock will begin trading on Nasdaq on October 25, maintaining the ticker symbol BTX. President and CEO Howard J. Federoff expressed optimism regarding the move, stating it aligns with the company's innovation focus, potentially appealing to a wider range of investors.

The company is advancing its IRX-2 therapy for head and neck cancer, currently in Phase 2B trials, following promising Phase 2A results. Brooklyn also has multiple therapies in preclinical development.

Brooklyn ImmunoTherapeutics, Inc. (NYSE American: BTX) announced on September 20, 2021, that Roger Sidhu was granted a non-qualified stock option for 161,300 shares and a restricted stock unit (RSU) for 80,650 shares. The options will vest over several years, contingent upon continued employment. These grants are intended to induce Dr. Sidhu's employment and are compliant with NYSE rules. Brooklyn focuses on cytokine and gene editing therapies for cancer and blood disorders, with its lead program, IRX-2, showing promise in Phase 2B trials for head and neck cancer.